Posted by Michael Wonder on 22 Apr 2021
New Brunswick becomes third province in Canada to implement biosimilar switching policy
21 April 2021 - Biosimilars Canada today congratulated the Government of New Brunswick for implementing a biosimilar "switching" or transitioning policy to expand the use of biosimilar medicines under the province's public drug plans.
New Brunswick's new biosimilar policy is expected to save the province more than $10 million annually when fully implemented, which will be reinvested to support coverage of new therapies.
